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ARTICLE
Outpatient diode laser treatment of intermediate-risk non-invasive bladder
tumors without sedation: efficacy, safety and economic analysis
Gregers Gautier Hermanna, Karin Mogensena and Susanne Rosthøjb
aDepartment of Urology, Herlev & Gentofte Hospitals, Copenhagen University, Hellerup, Denmark; bSection of Biostatistics Faculty of Health
and Medical Sciences, Institute of Public Health, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
Objective: This study aimed to validate a new method for outpatient diode laser ablation of bladder
tumors without sedation or pain control.
Methods: Twenty-one patients with stage Ta low-grade intermediate-risk bladder tumors underwent
photodynamic-guided laser ablation of their bladder tumors and 1 month later follow-up cystoscopy
with photodynamic and IMAGE1STM-guided biopsies. Pain was measured using a visual analog scale
(range 0–10). Symptoms and worries about the future disease course were calculated using the Quality
of Life Questionnaire for Non-Muscle-Invasive Bladder Cancer (range 0–100, high scores indicating
worse symptoms or worry). Costs of outpatient laser treatment versus inpatient conventional bladder
tumor resection in the operating theatre were compared.
Results: Patients had a median of three tumors (range 1–12). The median pain score was 1.0 (range
0–7) during laser ablation. Median quality of life scores were 24 (range 0–67) for symptoms and 42
(0–100) for worry. Two patients had minor hematuria and five had dysuria after laser therapy. Five
patients (24%) had new Ta low-grade recurrence within 13 months that was biopsied and laser treated.
No tumors progressed. Four patients had tumors identified using photodynamic diagnosis, and two
had flat low-grade dysplasia identified using IMAGE1S SPECTRA A and B and photodynamic diagnosis,
none of which was seen using white-light cystoscopy. Outpatient laser treatment could save about
e140,000 per million inhabitants versus inpatient bladder tumor surgery.
Conclusion: Fluorescence-guided diode lasers provide efficient and almost pain-free treatment of low-
grade urothelial cancer in conscious patients and could reduce healthcare costs.
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Approximately 55% of patients with urothelial cancer of the
bladder have low- or high-grade non-invasive bladder cancer.
The tumors are normally removed using transurethral resec-
tion of bladder tumors (TURBT) under general anesthesia dur-
ing a 1–2 day admission to a urology ward, preceded by
1 day of preparatory procedures. Within 5 years, 30–80% of
cases recur, but only 0–2% progress to invasive cancer dis-
ease [1]. Thus, non-invasive bladder cancer, in particular low-
grade cancer, is a chronic disease with frequent recurrences
requiring repeated TURBT and long-term monitoring.
Consequently, the lifetime cost of managing bladder cancer
per patient is among the highest of all cancers [1–4].
Substantial healthcare resources and burden on patients
could be spared if new technology could move the treatment
of non-invasive bladder tumors into an outpatient or office-
based setting. The authors have developed a method in which
a diode laser is used to devascularize and vaporize intermedi-
ate-risk stage Ta low-grade tumors in this setting, without the
use of sedation [5]. As sedation is not used, the patient can
leave the outpatient department immediately after the
endoscope (cystoscope) has been removed. This laser destruc-
tion of bladder tumors (LDB) appears to be less painful than
conventional outpatient cauterization and can therefore be
used to treat larger and more numerous tumors than
cauterization.
The aim of the present prospective study was to evaluate
the safety, tolerability, efficacy and economic impact of out-
patient LDB guided by photodynamic diagnosis (PDD) in the
management of patients with recurrent Ta low-grade bladder
tumors which have a low risk of disease progression.
Materials and methods
The study (ClinicalTrials.gov identifier: NCT02738827) was
approved by the regional ethical committee (H-15005804) and
the Danish Data Protection Agency (BFH-2015-054, I-Suite no.:
03964), and the Declaration of Helsinki (October 2013)
was followed.
Patients
The study involved 21 patients (median age 66 years; range
52–89 years) who had Ta low-grade intermediate-risk bladder
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tumors identified during outpatient surveillance by flexible
cystoscopy, where simultaneous biopsy verified the Ta low-
grade histology. Patients who qualified for the study and
gave written consent were booked for LDB within 1 week,
and follow-up cystoscopy and biopsy 1 month after LDB to
identify potential remnant tumor tissue. Inclusion criteria
were: recurrent Ta low-grade urothelial bladder tumor; tumor
size not larger than 1.5 cm, as larger tumors are difficult to
treat through the small flexible cystoscopes; and no more
than 15 tumors in the bladder. Exclusion criteria were:
ongoing use of anticoagulants and macroscopic hematuria,
as bleeding limits the view through the cystoscopes; preg-
nancy or breastfeeding; expected poor compliance; and age
less than 18 years.
Procedures
Both LDB and follow-up cystoscopy were fluorescence
guided using PDD (HexvixVR ; Photocure, Oslo, Norway) to opti-
mize the diagnosis of tumor tissue (Figure 1) [6]. A new com-
mercial technology, IMAGE1 STM (Karl Storz, Tuttlingen,
Germany), was used during the follow-up cystoscopy to
assess its potential value in the diagnosis of bladder tumor
recurrences after LDB. IMAGE1 S uses high-performance real-
time processing, without the need for an exogenous photo-
sensitizer, to improve the visualization of bladder details
(Figure 2).
For LDB, 50ml hexaminolevulinate (Hexvix; Photocure,
Oslo, Norway) and 20ml lidocaine anesthetic (20mg/ml)
were instilled into the bladder through a LoFric catheter
Ch 12 (Astra Tech, M€olndal, Sweden). Ibuprofen 600mg and
acetaminophen 1 g were also offered as oral pain treatment.
One hour later, LDB was performed using a flexible videocys-
toscope (11272 VPI, D-LIGHT C-LIGHT source; Karl Storz,
Tuttlingen, Germany). The bladder was first inspected in
white light while the urine was replaced with sterile water by
irrigation of the bladder twice through the cystoscope, as
urine hinders visualization during PDD by releasing green
autofluorescence when illuminated by blue light [7]. Then,
the illumination light was switched from white to blue light
and PDD was performed as blue-light cystoscopy. The loca-
tions of tumors observed in each modality were recorded on
a bladder map so that laser-treated areas could be biopsied
1 month later for assessing tumor clearance after LDB.
Through the working channel of the flexible cystoscope, a
laser fiber was introduced into the bladder. Laser treatment
was performed with a 980 nm diode laser, 220 V, with a
green 532 nm aiming beam and a front-firing 400 mm 0.22
numerical aperture bare laser fiber (Leonardo Laser, DUAL 45;
Biolitec Biomedical Technology, Jena, Germany). The laser
power was set to 8–15 W, with a pulse duration of 10ms at
10ms intervals. It was intended not to have contact between
the fiber tip and the target.
Urine cytology or other urine tests were not obtained as
these are not recommended for follow-up of low-grade non-
invasive bladder tumor disease in European Association of
Urology (EAU) and Danish guidelines.
To make sure that all tumor tissue was removed during
outpatient LDB, PDD and IMAGE1 S-guided flexible cystos-
copy and bladder biopsies of laser-treated areas were per-
formed 1 month later, thus assessing the efficacy of laser
therapy in terms of residual tumor rate. Biopsies were taken
from previously mapped and laser-treated tumor sites, and
images of the laser-treated area during PDD and IMAGE1 S
Figure 1. Bladder tumor stage Ta, low grade, illuminated with (A) white light and (B) blue light (photodynamic diagnosis) by flexible cystoscopy before laser
destruction of bladder tumor (LDB). (C) Mucosal lesions after LDB; the laser fiber can be seen on the right side of the picture.
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examination were recorded on video. The bladder was first
inspected in white light, then using five IMAGE1 S modalities
(CLARA, CHROMA, CLARA/CHROMA, SPECTRA A and SPECTRA
B) and eventually by PDD. This sequence was chosen as it is
known that PDD is superior to white-light cystoscopy in iden-
tifying bladder tumors. Simultaneous evaluation of PDD and
IMAGE1 S is not possible as the two modalities are not com-
mercially available in the same flexible cystoscope.
Patients were given adjuvant intravesical chemotherapy
instillations, according to guidelines.
Assessments
Pain experienced during LDB or cystoscopy was measured on
a visual analog scale (VAS) from 0 to 10. Postprocedure
symptoms were measured using the European Organisation
for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire for Non-Muscle-Invasive Bladder Cancer (QLQ-
NMIBC24). The QLQ-NMIBC24 has been validated in Danish
patients after TURBT under general anesthesia and has a
‘symptom score’ for lower urinary tract symptoms (LUTS) and
a ‘worry score’ for concerns about the future course of the
disease [8]. The range of both scores is 0–100, with higher
scores indicating worse LUTS or worry. The VAS was filled
out immediately after the laser procedure, whereas the QLQ-
NMIBC24 was completed on day 7 after LDB. A research
nurse called patients on day 5 to remind them to complete
the questionnaire and to ask about adverse events. After the
follow-up cystoscopy, patients were asked whether they pre-
ferred the inpatient or the outpatient procedure for future
tumor recurrences.
Bladder lesions were classified according to Union for
International Cancer Control/American Joint Committee on
Cancer stages [9] and WHO 2004 grades [10].
To assess the economic impact of outpatient LDB, public
reimbursement of inpatient TURBT and outpatient LDB based
on diagnosis-related groups [11] were compared.
Reimbursement in Denmark is based on the Danish National
Healthcare classification system [Sundheds-vaesenets
Klassifikations System (SKS)], which follows the International
Classification of Diseases, 10th revision, but is adapted to
Danish costs of surgical procedures. The SKS codes used
were KZXF45 for the PDD procedure, KKCD32 for TURBT and
DD303 for Ta low-grade bladder tumor [12]. A code for out-
patient LDB does not exist. Instead, the code for outpatient
cystoscopy and biopsy was used, and the cost of a laser fiber
was added. The number of TURBT procedures was obtained
from the Danish bladder cancer registry [13].
Statistical analysis
As a basic level of efficacy, the proportion of patients having
unbearable discomfort and side-effects hindering LDB should
be small. With a sample size of 21 and if the proportion of
patients with unbearable discomfort is 25%, the hypothesis
that less than 5% of the patients have unbearable discomfort
can be rejected with a power of 80%, using an exact bino-
mial test. The observed proportion of patients with discom-
fort was determined with a 95% exact confidence interval
(CI). Calculations were performed in R version 3.3.1.
Results
Patients had a median of three recurrent tumors each (range
1–12; tumor size 5–15mm). The median duration of cysto-
scopic examination and laser treatment was 29min (range
19–45min), and the median delivered laser effect was 700 J
(range 103–1840 J).
All patients had LDB performed as scheduled without sig-
nificant discomfort. The hypothesis that less than 5% of the
patients experience unbearable discomfort could not be
rejected (p¼ 1.00, 95% CI 0–16%). The median VAS score for
pain was 1.0 (range 0–7; only one patient recorded level 7)
during LDB and 0.3 (range 0–4) during follow-up cystoscopy
and biopsy. On the QLQ-NMIBC24 recorded after 7 days, the
median symptom score was 24 (range 0–67) and the median
worry score was 42 (range 0–100). Two patients (10%) had
minor hematuria for 24 h and five patients (24%) experienced
dysuria without bacteriuria for up to 4 days; none of these
symptoms required treatment, as no urinary infections were
recorded. No other symptoms were recorded. All patients
preferred to have outpatient LDB instead of inpatient TURBT
for future recurrences.
At 1 month cystoscopy, 19 (90%) of the 21 patients had
no tumor tissue in biopsies from laser-treated areas, whereas
two patients had remnant flat low-grade dysplasia. Over a
median follow-up of 14 months (range 12–16 months), five
patients (24%) experienced Ta low-grade recurrences, which
Figure 2. Bladder tumor stage Ta, low grade, examined by flexible cystoscopy using IMAGE1 S: (A) SPECTRA A; (B) SPECTRA B.
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were small (1–3mm) and could be immediately biopsied and
treated by laser. No patients had disease progression.
During LDB, PDD identified tumors that were not seen on
white light in four patients (19%). During follow-up cystos-
copy at 1 month, IMAGE1 S SPECTRA A and SPECTRA B set-
tings gave images that appeared to accentuate irregularities
in the mucosa and the contrast of vessels, more than
SPECTRA CLARA/CHROMA and CLARA did. SPECTRA A and B
identified flat low-grade dysplasia in two patients (10%),
which was also seen on PDD but not on white light or
CLARA/CHROMA or CLARA settings. The median duration of
PDD, IMAGE1 S and biopsy was 16min (range 9–34min).
Reimbursement for inpatient management of Ta low-
grade bladder tumor, i.e. hospital admission and PDD-guided
TURBT in the operating room, is e2508. Using the code for
outpatient PDD-guided cystoscopy and biopsy (e771) and
the price of a laser fiber (e135), reimbursement for PDD-
guided LDB was e906. Thus, the outpatient procedure offered
a e1602 cost reduction compared with inpatient manage-
ment. According to the Danish national bladder cancer regis-
try, about 1944 TURBT procedures are performed per year in
Denmark due to recurrent Ta low-grade tumors. Based on
clinical experience, the authors estimate that 25% of these
procedures (approximately 486 TURBTs for Ta low-grade) are
carried out for tumors less than 1.5 cm in size and fewer than
15 in number. These can therefore be removed with LDB in
the outpatient department. With a Danish population of
5.5 million, this equates to approximately 88 procedures per
million inhabitants that could be performed in the outpatient
department, achieving estimated direct cost savings of about
e140,000 per million inhabitants.
Discussion
This study indicates that outpatient laser treatment is safe
and causes little discomfort for patients with recurrent inter-
mediate-risk Ta low-grade bladder tumors. As no sedation is
used and symptoms are sparse, all patients were able to con-
tinue daily activities immediately after the procedure.
Previous reports on outpatient removal of bladder tumors
under local anesthesia are limited to the treatment of fragile
elderly patients and patients with multiple comorbidities, for
whom general anesthesia presents a high risk [14]. This art-
icle proposes a treatment modality that may be used for any
patient with a moderate tumor burden, and not only fragile
patients. The intention is that the tolerability of LDB will
allow patients to leave the outpatient department directly
after the procedure and return to their normal routine.
This study was limited to recurrent tumors to ensure that
patients had a reliable diagnosis of non-invasive low-grade
bladder cancer after conventional inpatient TURBT, so the
patient was not jeopardized by treatment of invasive aggres-
sive disease. Accordingly, primary tumors should not be
handled with LDB.
Furthermore, the low grade of tumor recurrence in
the present study was confirmed on biopsy before the laser
procedure to avoid high-grade disease and its higher risk of
progression. Other investigators have reported recurrence
rates up to 73% 3 months after inpatient yttrium aluminum
garnet (YAG) laser treatment of non-muscle-invasive bladder
cancer, including T1 disease [15]. A 6% progression rate in
the 2 years after outpatient holmium:YAG laser treatment has
been reported in patients with T1 high-grade tumors, com-
pared with no progression in those with Ta low-grade tumors
[16]. In the absence of substantial evidence on the efficacy of
outpatient laser treatment of bladder cancer, only Ta low-
grade disease was treated in this study, because the risk of
progression is low in these tumors.
This is the first report on the efficacy and usability of
diode lasers in the treatment of bladder tumors. A 980 nm
diode laser was chosen because of its significant optical
absorption coefficient for hemoglobin (50 cm1), which is suf-
ficient to heat and ensure coagulation of blood vessels in
tumors, thereby avoiding bleeding obscuring visualization [5].
Coagulation of blood vessels also induces ischemia and sub-
sequent exfoliation of remnant tumor tissue. Furthermore, a
low absorption coefficient in water (0.3 cm1) makes deep
tissue penetration possible, as measured up to 4.5mm, which
appears sufficient for influencing the entire tumor base and
stalk in exophytic tumors of this size [17].
The 24% recurrence rate in this study (five out of 21
patients over a median of 14 months) is similar to that
reported after treatment with holmium lasers and to the risk
tables in EAU guidelines [14,18–20]. Three of these recur-
rences appeared after 5 months and may have been residual
tumors after insufficient laser treatment, like the two cases of
remnant flat low-grade dysplasia in laser-treated tumor areas
identified at 1 month. These patients typically had either
many tumors or large tumors at the initial LDB, which need
expertise to eradicate with laser treatment. The recurrence
rate would be expected to decrease with increasing experi-
ence with the technique. In the meantime, residual tumor tis-
sue or small recurrences are easy to remove in the
outpatient department, without referral to the urology ward
for TURBT. In all cases of recurrence in this study, the patho-
logical lesions were immediately removed by laser therapy.
The benefits of PDD over white light to guide flexible
cystoscopy in the outpatient setting have been described
[21], but, there are only two reports of bladder examination
with IMAGE1 S [22,23]. The advantage of IMAGE1 S is its
instant use without preceding procedures. Although the
number of patients examined using IMAGE1 S in this study is
low, this experience suggests that further investigation of the
value of SPECTRA A and B, and whether they facilitate imme-
diate diagnosis of bladder tumors, is warranted.
The impact of LDB on patients, measured by the EORTC
QLC-NMIBC24, shows significant differences from TURBT. In a
population of similar patients undergoing inpatient TURBT,
the authors measured a symptom score of 45, which is dou-
ble the score in the LDB patients, indicating that TURBT is
more traumatizing than LDB. However, the worry score in
the TURBT study was 40 and thus similar to the score in the
present study, indicating that outpatient management with
LDB is not yet sufficient to alleviate patients’ concerns about
the future course of the disease [8].
The economic benefits of transferring inpatient TURBT to
outpatient LDB are substantial. In addition to the calculated
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cost reduction, operating room capacity is spared, so it can
be used for alternative surgical procedures. Working days
may also be spared and societal and personal costs thus
reduced as patients are able to return to their jobs immedi-
ately after LDB. However, if LDB replaces day-care surgical
procedures, the cost benefit may be slightly lower than esti-
mated owing to the lower cost of day care than inpatient
procedures. For patients, outpatient LDB is easier and much
less demanding, and, according to this study, is preferred by
patients over inpatient TURBT. Based on the results of the
present study, the method is now under evaluation in a
randomized controlled trial (ClinicalTrials.gov identifier:
NCT02886026).
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